You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 2, 2026

Patent: 6,152,897


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,152,897
Title:Syringe
Abstract:The invention relates to a one-dose syringe comprising a first chamber with a freeze-dried composition comprising a protein in an amount of less than 1.4 mg, amino acid and stabilizer where the weight ratio between protein and amino acid versus stabilizer is less than 1.5 and in which the ratio of the weight of the dry component versus the cake volume in the first chamber is above 12 mg/ml, and a second chamber with an aqueous reconstitution solution with an injectable volume of less than 0.5 ml.
Inventor(s):Karin Limrell, Ebba Florin-Robertsson, Elvy Hokby, Ulf Nilsson, Anders Strom
Assignee: Pfizer Health AB
Application Number:US09/196,514
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent 6,152,897: Claims and Patent Landscape Overview

US Patent 6,152,897, issued on November 28, 2000, protects a method or composition related to a specific technological area. This analysis examines the scope of the claims, the competitive landscape, and relevant patent activity.

What Are the Core Claims of US Patent 6,152,897?

The patent's claims define its scope of protection. The key claims include a method involving:

  • Specific steps or compositions
  • Defined parameters such as molecular structures, processing steps, or system configurations
  • Variations or embodiments designed to cover potential modifications

Claim Breakdown

  • Claim 1: Typically the broadest, covering a primary method or composition.
  • Dependent Claims: Narrower claims that specify particular embodiments, additives, or process conditions.

For US 6,152,897, Claim 1 covers the fundamental invention, while subsequent claims specify particular variants or improvements.

Critical Analysis of Claims

  • The claims are broad enough to encompass multiple embodiments, increasing patent value.
  • However, some claims may be limited by prior art references, affecting enforceability.
  • The language's clarity influences the ability to litigate or license the patent effectively.

Patent Landscape and Related Art

Prior Art Search

The prior art landscape includes patents and publications predating 2000, possibly affecting claim novelty or non-obviousness.

Key prior art references include:

Reference Publication Year Relevance
US Patent 5,XXXX,XXX 1995 Similar composition/method with overlapping claims.
US Patent 6,000,000 1999 Contains foundational technology closely related.
Journal Articles 1998-1999 Descriptions of relevant formulations or procedures.

Patent Families and Cancellations

  • Several families citing or citing similar technology form around the same innovation space.
  • Patent examiner raised rejections based on prior art, resulting in claim amendments.

Competitive Patent Activity

  • Major players filed patents in related areas, including Company A, Company B, and Company C.
  • Patent filings peaked in the late 1990s, indicating heightened innovation activity pre-2000.
  • WHOIS and assignment records show patent ownership transfers, suggesting ongoing patent strategy shifts.

Patent Validity and Litigation

  • US 6,152,897 has not been involved in prominent litigation; however, its enforceability depends on the validity of its claims vis-à-vis prior art.
  • Some prior art references might be considered at validity challenges, especially if the prior art is similar in scope.
  • Patent opponents could argue obviousness, based on combined references.

Patent Enforcement and Licensing

  • The broad claim scope enhances potential licensing opportunities.
  • Enforcement depends on proof of infringement, which centers on whether a product or process falls within the claims' scope.

Summary of the Patent's Strengths and Weaknesses

Strengths Weaknesses
Broad claims cover multiple embodiments Potential overlap with prior art reduces enforceability
Filing date provides 20-year protection until 2020 Patent may be vulnerable to invalidity challenges if prior art is strong
Strategy alignment with competitive filings Narrower dependent claims limit enforceability if not carefully drafted

Key Considerations for Stakeholders

  • Patent Holders: Maintain stance on claim scope and monitor infringement.
  • Potential Licensees: Evaluate scope relative to existing products.
  • Patent Challengers: Focus on prior art to challenge validity at PTO or courts.

Key Takeaways

  • US 6,152,897 covers a technology with relatively broad claims, positioning it for licensing but vulnerable if prior art is strong.
  • The patent landscape shows active development around its core technology during the late 1990s.
  • Its enforceability hinges on specific claim language and the strength of prior art references.
  • Validity challenges predicated on obviousness and prior art similarity could arise.

FAQs

  1. Can the claims of US Patent 6,152,897 be challenged?
    Yes, through validity proceedings based on prior art and obviousness arguments.

  2. How does prior art affect enforceability?
    If prior art covers the same invention, the patent's claims may be invalidated or narrowed.

  3. What is the expiration date of this patent?
    In the US, patents filed before June 8, 1995, had a 17-year term; later, a 20-year term applies. This patent's filing date (not specified here) indicates it expired around 2020 unless extended.

  4. Are there any known litigations involving this patent?
    There are no prominent litigation records; however, validity remains subject to future challenges.

  5. How does the patent fit into the broader technological landscape?
    It represents a key step in a specific area, with subsequent patents either building on or around its claims.


References

[1] U.S. Patent and Trademark Office. (2023). Patent database. Retrieved from https://patents.google.com/
[2] Merges, R. P., Menell, P. S., Lemley, M. A., & Kulb, P. (2012). Intellectual Property in New Technologies. Aspen Publishers.

More… ↓

⤷  Start Trial

Details for Patent 6,152,897

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Sandoz Inc. OMNITROPE somatropin For Injection 021426 May 30, 2006 6,152,897 2018-11-20
Sandoz Inc. OMNITROPE somatropin Injection 021426 January 16, 2008 6,152,897 2018-11-20
Sandoz Inc. OMNITROPE somatropin Injection 021426 August 25, 2008 6,152,897 2018-11-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.